JTJean-Francois Thibodeau

Jean-Francois Thibodeau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jean-Francois Thibodeau has a total of 100 co-authors. Here are the top co-authors by number of shared publications:

  • Chet E. Holterman

    Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada K1H 8M5

    5 shared publications
  • Christopher R.J. Kennedy

    Kidney Research Center, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

    5 shared publications
  • Brigitte Grouix

    Prometic Biosciences Inc., Laval, QC, Canada

    3 shared publications
  • Jean-Christophe Simard

    Prometic Biosciences Inc., Laval, QC, Canada

    3 shared publications
  • Rania Nasrallah

    Department of Cellular and Molecular Medicine, Faculty of Medicine, Kidney Research Centre, University of Ottawa, Ottawa, ON, Canada

    3 shared publications
  • Richard L. Hébert

    Kidney Research Center, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

    3 shared publications

Latest Publications

  • Vascular contributions to 16p11.2 deletion autism syndrome modeled in mice

    by Julie Ouellette, Xavier Toussay, Cesar H. Comin, Luciano da F. Costa, Mirabelle Ho, María Lacalle-Aurioles, Moises Freitas-Andrade, Qing Yan Liu, Sonia Leclerc, Youlian Pan, et al.

    While the neuronal underpinnings of autism spectrum disorder (ASD) are being unraveled, vascular contributions to ASD remain elusive. Here, we investigated postnatal cerebrovascular development in the 16p11.2df/+ mouse model of 16p11.2 deletion ASD syndrome. We discover that 16p11.2 hemizygosity leads to male-specific, endothelium-dependent structural and functional neurovascular abnormalities. In 16p11.2df/+ mice, endothelial dysfunction results in impaired cerebral angiogenesis at postnatal day 14, and in altered neurovascular coupling and cerebrovascular reactivity at postnatal day 50. Moreover, we show that there is defective angiogenesis in primary 16p11.2df/+ mouse brain endothelial cells and in induced-pluripotent-stem-cell-derived endothelial cells from human carriers of the 16p11.2 deletion. Finally, we find that mice with an endothelium-specific 16p11.2 deletion (16p11.2ΔEC) partially recapitulate some of the behavioral changes seen in 16p11.2 syndrome, specifically hyperactivity and impaired motor learning. By showing that developmental 16p11.2 haploinsufficiency from endothelial cells results in neurovascular and behavioral changes in adults, our results point to a potential role for endothelial impairment in ASD.


  • PBI-4050 via GPR40 activation improves adenine-induced kidney injury in mice

    by Jean-François Thibodeau, Jean-Christophe Simard, Chet E. Holterman, Amélie Blais, Marie-Pier Cloutier, Thalia Medeiros, Martin Leduc, Brigitte Grouix, François A. Leblond, Dylan Burger, et al.

    PBI-4050 (3-pentylbenzenacetic acid sodium salt), a novel first-in-class orally active compound that has completed clinical Phases Ib and II in subjects with chronic kidney disease (CKD) and metabolic syndrome respectively, exerts antifibrotic effects in several organs via a novel mechanism of action, partly through activation of the G protein receptor 40 (GPR40) receptor. Here we evaluate the effects of PBI-4050 in both WT and Gpr40−/− mice on adenine-induced tubulointerstitial injury, anemia and activation of the unfolded protein response (UPR) pathway. Adenine-induced CKD was achieved in 8-week-old C57BL/6 mice fed a diet supplemented with 0.25% adenine. After 1 week, PBI-4050 or vehicle was administered daily by oral-gavage for 3 weeks. Gpr40−/− mice were also subjected to adenine-feeding, with or without PBI-4050 treatment. PBI-4050 improved renal function and urine concentrating ability. Anemia was present in adenine-fed mice, while PBI-4050 blunted these effects and led to significantly higher plasma erythropoietin (EPO) levels. Adenine-induced renal fibrosis, endoplasmic reticulum (ER) stress and apoptosis were significantly decreased by PBI-4050. In parallel, Gpr40−/− mice were more susceptible to adenine-induced fibrosis, renal function impairment, anemia and ER stress compared with WT mice. Importantly, PBI-4050 treatment in Gpr40−/− mice failed to reduce renal injury in this model. Taken together, PBI-4050 prevented adenine-induced renal injury while these beneficial effects were lost upon Gpr40 deletion. These data reinforce PBI-4050’s use as a renoprotective therapy and identify GPR40 as a crucial mediator of its beneficial effects.


  • FRI-097-PBI-4050 treatment decreases sepsis-induced liver injury in mice

    by Jean-François Thibodeau, Brigitte Grouix, Jean-Christophe Simard, Chet Holterman, Alex Gutsol, Alexandra Blais, Alexandre Laverdure, Richard Hébert, François Leblond, Pierre Laurin, et al.

  • Open Access

    GRK2 knockdown in mice exacerbates kidney injury and alters renal mechanisms of blood pressure regulation

    by Elena Tutunea-Fatan, Khaled S. Abd-Elrahman, Jean-Francois Thibodeau, Chet E. Holterman, Brian J. Holleran, Richard Leduc, Christopher R. J. Kennedy, Robert Gros, Stephen S. G. Ferguson

    The renin-angiotensin system regulates blood pressure and fluid balance in the body primarily via angiotensin receptor 1 (AT1R). Renal AT1R was found to be primarily responsible for Ang II-mediated hypertension. G protein-coupled receptor kinase 2 (GRK2) modulates AT1R desensitization and increased GRK2 protein expression is reported in hypertensive patients. However, the consequences of GRK2 inhibition on kidney functions remain unknown. We employed shGRK2 knockdown mice (shGRK2 mice) to test the role of GRK2 in kidney development and function that can be ultimately linked to the hypertensive phenotype detected in shGRK2 mice. GRK2 knockdown reduced kidney size, nephrogenesis and glomerular count, and impaired glomerular filtration. Glomerular damage in adult shGRK2 mice was associated with increased renin- and AT1R-mediated production of reactive oxygen species. The AT1R blocker, Losartan, normalized elevated blood pressure and markedly improved glomerular filtration in the shGRK2 knockdown mice. Our findings provide evidence for the crucial role of GRK2 in renal regulation of blood pressure. It also suggests that the detrimental outcomes of GRK2 inhibitors on the kidney should be carefully examined when used as antihypertensive.


  • Open Access

    A Newly Discovered Antifibrotic Pathway Regulated by Two Fatty Acid Receptors

    by Lyne Gagnon, Martin Leduc, Jean-Francois Thibodeau, Ming-Zhi Zhang, Brigitte Grouix, Francois Sarra-Bournet, William Gagnon, Kathy Hince, Mikaël Tremblay, Lilianne Geerts, et al.


  • Open Access

    PGE2 EP1 receptor inhibits vasopressin-dependent water reabsorption and sodium transport in mouse collecting duct

    by Rania Nasrallah, Joseph Zimpelmann, David Eckert, Jamie Ghossein, Sean Geddes, Jean-Claude Beique, Jean-Francois Thibodeau, Chris R J Kennedy, Kevin D Burns, Richard L Hébert


  • Vascular Smooth Muscle-Specific EP4 Receptor Deletion in Mice Exacerbates Angiotensin II-Induced Renal Injury

    by Jean-Francois Thibodeau, Chet E. Holterman, Ying He, Anthony Carter, Gregory O. Cron, Naomi C. Boisvert, Khaled S. Abd-Elrahman, Karolynn J. Hsu, Stephen S.G. Ferguson, Christopher R.J. Kennedy

    Aims: Cyclooxygenase inhibition by non-steroidal anti-inflammatory drugs is contraindicated in hypertension, as it may reduce glomerular filtration rate (GFR) and renal blood flow. However, the identity of the specific eicosanoid and receptor underlying these effects is not known. We hypothesized that vascular smooth muscle prostaglandin E2 (PGE2) E-prostanoid 4 (EP4) receptor deletion predisposes to renal injury via unchecked vasoconstrictive actions of angiotensin II (AngII) in a hypertension model. Mice with inducible vascular smooth muscle cell (VSMC)-specific EP4 receptor deletion were generated and subjected to AngII-induced hypertension. Results: EP4 deletion was verified by PCR of aorta and renal vessels, as well as functionally by loss of PGE2-mediated mesenteric artery relaxation. Both AngII-treated groups became similarly hypertensive, whereas albuminuria, foot process effacement, and renal hypertrophy were exacerbated in AngII-treated EP4 VSMC−/− but not in EP4 VSMC+/+ mice and were associated with glomerular scarring, tubulointerstitial injury, and reduced GFR. AngII-treated EP4 VSMC−/− mice exhibited capillary damage and reduced renal perfusion as measured by fluorescent bead microangiography and magnetic resonance imaging, respectively. NADPH oxidase 2 (Nox2) expression was significantly elevated in AngII-treated EP4 −/− mice. EP4-receptor silencing in primary VSMCs abolished PGE2 inhibition of AngII-induced Nox2 mRNA and superoxide production. Innovation: These data suggest that vascular EP4 receptors buffer the actions of AngII on renal hemodynamics and oxidative injury. Conclusion : EP4 agonists may, therefore, protect against hypertension-associated kidney damage. Antioxid. Redox Signal . 25, 642–656.


  • Prostaglandin E2 increases proximal tubule fluid reabsorption, and modulates cultured proximal tubule cell responses via EP1 and EP4 receptors

    by Rania Nasrallah, Ramzi Hassouneh, Joseph Zimpelmann, Andrew J Karam, Jean-Francois Thibodeau, Dylan Burger, Kevin D Burns, Chris Rj Kennedy, Richard L Hébert


  • NADPH oxidase 5 and renal disease

    by Chet E. Holterman, Jean F. Thibodeau, Christopher R.J. Kennedy

    To highlight the latest novel developments in renal NADPH oxidase 5 (Nox5) biology, with an emphasis not only on diabetic nephropathy but also on many of the other renal disease contexts in which oxidative stress is implicated. Nox-derived reactive oxygen species have been shown to contribute to a wide variety of renal diseases, particularly in the settings of chronic renal disease such as diabetic nephropathy. Although much emphasis has been placed on the role of NADPH oxidase 4 in this setting, a growing body of work continues to uncover the key roles for other Nox family members, not only in diabetic kidney disease, but also in a diverse array of renal pathological conditions. The most recently identified member of the Nox family, Nox5, has for the most part been overlooked in renal disease, partly owing to its absence from the rodent genome. New evidence suggests that Nox5 may be a contributing factor in glomerulopathies and altered tubular physiology. Furthermore, Nox5 appears to harbor a significant number of single-nucleotide polymorphisms that alter its enzymatic activity. Given the unique structure and expression pattern of Nox5, it may prove to be an attractive therapeutic target in the treatment of renal disease.


  • Open Access

    A Novel Mouse Model of Advanced Diabetic Kidney Disease

    by Jean-Francois Thibodeau, Chet E. Holterman, Dylan Burger, Naomi C. Read, Timothy L. Reudelhuber, Christopher R. J. Kennedy

    Currently available rodent models exhibit characteristics of early diabetic nephropathy (DN) such as hyperfiltration, mesangial expansion, and albuminuria yet features of late DN (hypertension, GFR decline, tubulointerstitial fibrosis) are absent or require a significant time investment for full phenotype development. Accordingly, the aim of the present study was to develop a mouse model of advanced DN with hypertension superimposed (HD mice). Mice transgenic for human renin cDNA under the control of the transthyretin promoter (TTRhRen) were employed as a model of angiotensin-dependent hypertension. Diabetes was induced in TTRhRen mice through low dose streptozotocin (HD-STZ mice) or by intercrossing with OVE26 diabetic mice (HD-OVE mice). Both HD-STZ and HD-OVE mice displayed more pronounced increases in urinary albumin levels as compared with their diabetic littermates. Additionally, HD mice displayed renal hypertrophy, advanced glomerular scarring and evidence of tubulointerstitial fibrosis. Both HD-OVE and HD-STZ mice showed evidence of GFR decline as FITC-inulin clearance was decreased compared to hyperfiltering STZ and OVE mice. Taken together our results suggest that HD mice represent a robust model of type I DN that recapitulates key features of human disease which may be significant in studying the pathogenesis of DN and in the assessment of putative therapeutics.